Firehawk<sup>®</sup> Receives Approval from Vietnam's Ministry of Health

Hanoi, Vietnam – On August 22, Shanghai MicroPort Medical (Group) Co (MicroPort®) announced that its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") received approval from Vietnam's Ministry of Health.
 
Firehawk® is MicroPort®'s third generation drug-eluting stent ("DES"), used for the treatment of coronary artery stenosis and occlusion following Firebird® Rapamycin-Eluting Coronary Stent and Firebird2® Rapamycin-Eluting Coronary CoCr Stent. It is the world's first and only target eluting stent ("TES"), adopting TARGET Eluting Technique to achieve free redundancy. Its automatic and ultra-micro 3D printing technology enables groove filling, which means that the absorbable drug coating is filled in the groove while the other area of the stent has metal surface. Such unique technology makes Firehawk® combine the merits of bare metal stents and DES, which can lower the incidence of long-term stent thrombosis and in-stent restenosis.
 
Firehawk® received the registration certificate from China Food and Drug Administration and the CE Mark approval from the European Notified Body, and was approved for market launch in Thailand, the Philippines, Indonesia, Peru, Brazil, India and Argentina. Vietnam is an important market in Southeast Asia, and as Firehawk® received approval from Vietnam's Ministry of Health in Vietnam, it will help further expand MicroPort®'s overseas market and provide more ideal surgical solutions for local patients.